Niki BioSolutions Inc. (NIKI) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Niki BioSolutions Inc. (NASDAQ: NIKI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.96 (+1.88% 1D, market cap $5.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 485 tracked Industrials issuers, NIKI ranks #398 in composite RQD confidence.
Within the Industrials sector (Industrial Machinery/Components), NIKI carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -5.9%. By comparison, UCAR (U Power Limited (Class A)) holds a E grade (19/100 RQD, P/E N/A, ROIC -18.5%, cap $5.1M) and RETO (ReTo Eco-Solutions Inc. (Class A)) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M). Among the 5-stock peer group, NIKI leads on earnings multiple (N/A) while NIKI leads on capital efficiency (-5.9% ROIC).
Per NIKI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001734005), Niki BioSolutions Inc. generated $0 in revenue, -$1.4M in net income, and -$1.8M in free cash flow against $18.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Industrials with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 27.1 (OVERSOLD (<32))
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While NIKI currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Industrials with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.50) and Max Pain ($2.06) forces dealer call-delta covering toward $18.06.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Niki BioSolutions Inc. (NIKI) advanced +1.88% to $1.96, trading at 2% of its 52-week range ($1.7 – $17.2). Stretched risk/reward at current multiples (-6% return on capital) under elevated 10-year interest-rate pressure.
NYSDOH CLEP approval extends validated APOE genotyping beyond blood, buccal swab, saliva, and tissue for clinical and research use NEW HAVEN, CT and PRINCETON, NJ, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc
Niki BioSolutions, Inc. (NASDAQ: NIKI) ("Niki BioSolutions" or the "Company"), a clinical-stage life sciences company focused on developing advanced genomic and biomarker testing solutions, today
Agreement brings CAP and NYS CLEP-approved genotyping test to a multi-site Alzheimer’s clinical research network PRINCETON, NJ, NEW HAVEN, CT and ORLANDO, FL, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NA
Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 19.3% to $1.14 during Tuesday's after-market session. The company's market cap stands at $1.8 million. Edesa Biotech (NASDAQ:EDSA) shares rose
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NIKI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NIKI. Explore sector supply chains on /butterfly.
Across 485 tracked Industrials securities in the Roarable RQD universe, Niki BioSolutions Inc. (NIKI) ranks #398 by composite RQD confidence (32/100, grade E) and #458 by equity capitalization ($5.7M). Within this direct 5-issuer industry benchmark cohort, NIKI leads on earnings valuation at N/A trailing P/E, while NIKI leads on capital efficiency and profitability with -5.9% ROIC and — gross margin. XPON currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with NIKI at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NIKI
ACTIVE
Niki BioSolutions Inc. | E | 32/100 | — | — | -5.9% | +1.88% | $5.7M | Benchmark Subject |
| UCAR U Power Limited (Class A) | E | 19/100 | — | 36.3% | -18.5% | -5.00% | $5.1M | /ucar-vs-niki → |
| RETO ReTo Eco-Solutions Inc. (Class A) | E | 29/100 | — | 35.3% | -35.0% | -21.03% | $4.7M | /reto-vs-niki → |
| DFLI Dragonfly Energy Holdings Corp. (NV) | E | 25/100 | — | 26.7% | -35.0% | +3.11% | $4.3M | /dfli-vs-niki → |
| XPON Expion Energy Inc. | D- | 35/100 | — | 13.9% | -35.0% | +5.20% | $4.1M | /xpon-vs-niki → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Niki BioSolutions Inc. (NIKI) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$1.4M, operating cash flow of -$1.8M, and free cash flow of -$1.8M (-54.4% YoY). On the balance sheet, NIKI closed FY2025 with $18.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$1.4M | -$1.8M | -$1.8M | $18.7M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$4.3M | -$1.2M | -$1.2M | $16.1M | — |
| FY2023 (FY) | 2023-12-31 | $431.4K | -$2.8M | -$7.7M | -$7.7M | — | — |
As of 2026-11-02, Niki BioSolutions Inc. (NASDAQ: NIKI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.96 (+1.88% 1D, market cap $5.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 485 tracked Industrials issuers, NIKI ranks #398 in composite RQD confidence.
Within the Industrials sector (Industrial Machinery/Components), NIKI carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -5.9%. By comparison, UCAR (U Power Limited (Class A)) holds a E grade (19/100 RQD, P/E N/A, ROIC -18.5%, cap $5.1M) and RETO (ReTo Eco-Solutions Inc. (Class A)) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M). Among the 5-stock peer group, NIKI leads on earnings multiple (N/A) while NIKI leads on capital efficiency (-5.9% ROIC).
Per NIKI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001734005), Niki BioSolutions Inc. generated $0 in revenue, -$1.4M in net income, and -$1.8M in free cash flow against $18.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Industrials with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
NIKI last traded at $1.96 (+1.88% on volume of 5,575 shares), positioning the stock -56.44% below its 50-day simple moving average ($4.50) and -74.45% below its 200-day simple moving average ($7.67). Across its 52-week range of $1.70 to $17.20, NIKI sits at the 1.7% percentile with a 14-day RSI of 27.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.72 to $2.20).
Why NIKI Stock advanced +1.88% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-6% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).